ProSomnus initiated with a Buy at Alliance Global Partners

Alliance Global Partners initiated coverage of ProSomnus with a Buy rating and $2 price target. ProSomnus is a medical technology company developing, manufacturing, and selling nighttime dental appliances for the treatment of obstructive sleep apnea, or OSA, notes the analyst, who believes that the ProSomnus EVO dental appliance can “drive significant revenue growth and ultimately profits.”